Drugs / Roniciclib
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02457351 | Jul 2015 → Feb 2016 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02390154 | Apr 2015 → Mar 2016 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02047890 | May 2014 → Jan 2015 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01335256 | Dec 2010 → Sep 2011 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01188252 | Aug 2010 → Jun 2016 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02522910 | Aug 2015 → Aug 2016 | non-small cell lung carcinoma | Yonsei University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01573338 | Feb 2013 → Mar 2016 | small cell lung carcinoma | Bayer | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02656849 | Feb 2016 → Oct 2019 | cancer | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02161419 Comparator | Jul 2014 → Dec 2015 | small cell lung carcinoma | Bayer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Roniciclib | “BAY 1000394 (Roniciclib) in combination with docetaxel” NCT02522910 ↗ |
| Known as | BAY1000394 | “Orally Administered [14C]-Roniciclib (BAY 1000394)” NCT02390154 ↗8“Roniciclib (BAY 1000394)” NCT02457351 ↗ “Roniciclib (BAY1000394)” NCT01573338 ↗ “Roniciclib (BAY1000394)” NCT02161419 ↗ “Roniciclib (BAY1000394)” NCT01188252 ↗ |
| Action | Inhibit | “The study drug is a pan-CDK inhibitor” NCT02656849 ↗ |
| Modality | Small molecule | — CHEMBL4442620 ↗ |
| Route | Oral | “Oral administration twice daily” NCT01188252 ↗ |